
## PrzemysÅ,aw Holko

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5660382/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatology International, 2018, 38, 189-201.	1.5	45
2	Systematic review/Meta-analysis Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Archives of Medical Science, 2012, 5, 767-775.	0.4	40
3	Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Archives of Medical Science, 2018, 14, 1125-1136.	0.4	37
4	Sodium Orthovanadate Affects Growth of Some Human Epithelial Cancer Cells (A549, HTB44, DU145). Folia Biologica, 2008, 56, 115-121.	0.1	32
5	Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. Expert Review of Anticancer Therapy, 2014, 14, 63-73.	1.1	23
6	Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland. PLoS ONE, 2016, 11, e0168586.	1.1	22
7	Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012–2014. European Journal of Gastroenterology and Hepatology, 2018, 30, 456-464.	0.8	17
8	Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study. European Journal of Gastroenterology and Hepatology, 2018, 30, 174-180.	0.8	16
9	Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. Pharmacoeconomics, 2018, 36, 853-865.	1.7	14
10	Cost-utility analysis of Ruconest ® (conestat alfa) compared to Berinert® P (human C1 esterase) Tj ETQq0 0 C angioedema. Postepy Dermatologii I Alergologii, 2013, 3, 152-158.	) rgBT /Ov 0.4	erlock 10 Tf 5 13
11	Impact of Biologic Treatment of Crohn's Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland. Frontiers in Pharmacology, 2018, 9, 621.	1.6	9
12	Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting. Kardiologia Polska, 2015, 73, 768-780.	0.3	9
13	Budget Impact Analysis Of Hypertensive Treatment With Indapamide And Amlodipine Single-Pill Combination In The Polish Setting. Value in Health, 2014, 17, A479.	0.1	2
14	Cost-Utility Analysis Of Hypertensive Treatment With Indapamide And Amlodipine Single-Pill Combination In The Polish Setting. Value in Health, 2014, 17, A491.	0.1	2
15	Comment on: "Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review― PharmacoEconomics - Open, 2017, 1, 69-70.	0.9	2
16	PIN34 ECONOMIC ASSESSMENT OF MASS VACCINATION WITH PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE (PHID-CV) IN POLAND. Value in Health, 2009, 12, A423.	0.1	1
17	Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2011, 4, 79.	1.1	1
18	PIN83 Cost-Effectiveness and Cost-Utility analysis of 200 Days Prophylaxis of Cytomegalovirus (CMV) infections in High Risk (D+/R-) Kidney Transplant Recipients in Poland. Value in Health, 2011, 14, A280-A281.	0.1	0

#	Article	IF	CITATIONS
19	PND44 Cost-Utility Analysis and Cost-Minimisation Analysis of Sabril® (Vigabatrin) in Drug-Resistant Epilepsy From Payer's Perspective in Poland. Value in Health, 2012, 15, A553.	0.1	Ο
20	A Comment on Craig et al.: â€~â€~Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization: A NICE Single Technology Appraisal''. Pharmacoeconomics, 2013, 31, 533-535.	1.7	0
21	Anakinra in the treatment of rheumatoid arthritis in adult patients with an inadequate response to methotrexate. Systematic review and meta-analysis. Reumatologia, 2013, 2, 119-126.	0.5	Ο
22	Direct Costs Of Inflammatory Bowel Diseases Therapy In Poland - Nationwide Database Analysis. Value in Health, 2017, 20, A553.	0.1	0